CHELMSFORD, Mass., Jan. 12, 2021 /PRNewswire/ -- Brooks
Automation, Inc. (Nasdaq:BRKS) announced today that GENEWIZ,
the Company's genomics analysis business, has been awarded one of
six Genome Characterization Center Indefinite Delivery
Indefinite Quantity (IDIQ) contracts from the National Cancer
Institute (NCI). The NCI, the nation's leader in cancer research
and part of the National Institutes of Health (NIH), chose GENEWIZ
to provide whole exome sequencing to new research projects at its
Center for Cancer Genomics for a period of three years.
"This contract for Brooks to provide whole exome sequencing to
the National Cancer Institute demonstrates the outstanding
reputation of GENEWIZ in the cancer research community,"
commented Steve Schwartz, president and CEO of Brooks
Automation. "We are proud that GENEWIZ's expertise in gene
sequencing is an enabling factor for the important research at the
NCI, and for the enduring benefit of cancer patients."
"The data NCI generates for the entire cancer research community
across the nation supports the mission to advance scientific
knowledge and help all people live longer, healthier lives," shared
Dr. Ginger Zhou, vice president of
genomics services at GENEWIZ. "We are honored to become an integral
part of this initiative."
GENEWIZ will generate data from DNA samples received from the
Biospecimen Core Resource and send raw sequencing data, associated
metadata, and other characterization data to the Genomic Data
Commons. This data will then be shared with the Genomic Data
Analysis Network and research community.
The Center for Cancer Genomics coordinates research teams across
the United States and Canada to produce rich cancer genomic and
clinical datasets for the cancer research community. They implement
these collective efforts through a standardized workflow called the
Genome Characterization Pipeline. Components of this pipeline
include tissue collecting and processing, genome characterization,
genomic data analysis, as well as data sharing and discovery.
About Brooks Automation
Brooks (Nasdaq: BRKS) is a
leading provider of life science sample-based solutions and
semiconductor manufacturing solutions worldwide. The Company's
Life Sciences business provides a full suite of reliable cold-chain
sample management solutions and genomic services across areas such
as drug development, clinical research and advanced cell therapies
for the industry's top pharmaceutical, biotech, academic and
healthcare institutions globally. Brooks Life Sciences' GENEWIZ
division is a leading provider of gene sequencing and gene
synthesis services. With over 40 years as a partner to the
semiconductor manufacturing industry, Brooks is a provider of
industry-leading precision vacuum robotics, integrated automation
systems and contamination control solutions to the world's leading
semiconductor chip makers and equipment manufacturers. Brooks
is headquartered in Chelmsford, MA, with operations
in North America, Europe and Asia. For more
information, visit www.brooks.com.
BROOKS INVESTOR CONTACT:
Sherry Dinsmore
Brooks Automation
978.262.4301
sherry.dinsmore@brooks.com
John Mills
Managing Partner
ICR, LLC
646.277.1254
john.mills@icrinc.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/brooks-announces-genewiz-selected-as-genome-characterization-center-by-the-national-cancer-institute-301206883.html
SOURCE Brooks Automation